Titre | A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation |
Protocole ID | 20170543 (CodeBreaK 100) |
ClinicalTrials.gov ID | NCT03600883 |
Type(s) de cancer | Poumon non à petites cellules Tumeurs solides |
Phase | Phase I-II |
Type étude | Clinique |
Médicament | AMG 510 |
Institution |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN 1001 boul. Décarie , Montréal, QC, H4A 3J1 |
Ville | Montréal |
Investigateur(trice) principal(e) |
Dr Benjamin Shieh |
Coordonnateur(trice) |
Nicola Raby 514-934-1934 poste 34095 |
Statut | Fermé |
Critètes d'éligibilité |
|
Critètes d'exclusion |
|